Navigation Links
Proteolix Presents Clinical Data from Two Clinical Studies of Carfilzomib in Multiple Myeloma at the 14th Congress of the European Hematology Association
Date:6/8/2009

SOUTH SAN FRANCISCO, Calif., June 8 /PRNewswire/ -- Proteolix, Inc. today announced data from ongoing Phase 2 and Phase 1b clinical trials of carfilzomib for the treatment of multiple myeloma at the 14th Congress of the European Hematology Association (EHA) in Berlin, Germany. Carfilzomib is the first in a new class of selective, irreversible proteasome inhibitors being developed by Proteolix for the treatment of hematologic malignancies and solid tumors.

Relapsed Multiple Myeloma Patients Achieve Responses with Single-Agent Carfilzomib

Keith Stewart, M.B., Ch.B., Professor, Division of Hematology/Oncology at the Mayo Clinic, Arizona presented positive data from an ongoing Phase 2 clinical trial of single-agent carfilzomib in relapsed multiple myeloma patients. Patients in the study have relapsed after receiving one to three prior therapies and are stratified according to prior exposure to bortezomib.

A total of 31 patients have been enrolled in the Phase 2 clinical trial to date, of which 45 percent had no prior bortezomib experience and 55 percent relapsed following bortezomib treatment. In both arms, substantial response rates were achieved and sustained. Bortezomib-naive patients achieved an overall response rate of 57 percent with a median duration of response of 8.5 months. The median time to progression in this cohort has not been reached.

Among patients with prior bortezomib exposure, 18 percent achieved partial responses and the median duration of response has not yet been reached in this population. The median time to progression for patients in this cohort was 8.9 months. Ten additional patients achieved stable disease.

"Carfilzomib monotherapy achieves durable responses in relapsed multiple myeloma patients regardless of their prior exposure to bortezomib, and notably, a number of patients remain progression free after twelve cycles," said Dr. Stewart.
'/>"/>

SOURCE Proteolix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Proteolixs Carfilzomib Receives Orphan Drug Designation for Treatment of Multiple Myeloma
3. Proteolix Raises $79 Million in Series C Financing
4. Proteolix Presents Preclinical Data for Oral Proteasome Inhibitor PR-047 at the 50th Annual Meeting of the American Society of Hematology
5. Proteolix Announces Positive Data From Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Multiple Myeloma at the 50th Annual Meeting of the American Society of Hematology
6. Proteolix Announces New Appointment in Finance and Expands Clinical and Regulatory Leadership Team
7. Proteolix to Present Carfilzomib Clinical Data During the 2009 ASCO Annual Meeting
8. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
9. Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health
10. Touching 418 Million Lives, Hepatitis Still Presents Significant Threat to Global Health
11. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... New York , May 21, 2013 ... by Transparency Market Research ( http://www.transparencymarketresearch.com ) "Biochip Products ... Research, IVD Tests) - U.S. Industry Analysis, Size, Share, Growth, ... 2.4 billion in 2011 and is expected to grow ... to reach an estimated value of USD 4.7 billion ...
(Date:5/21/2013)... Norristown, PA (PRWEB) May 21, 2013 ... company, today announced that Dr. Charles Signorino, the Company’s ... on April 1, 2013 after 32 years of service. ... Adolfo Gomez, Emerson’s current President, has been named as ... recognized luminary in the pharmaceutical industry, having made a ...
(Date:5/21/2013)... BALTIMORE , May 21, 2013  Personal ... will use its proprietary methodologies and expertise in ... novel kinase targets in collaboration with Blueprint Medicines. ... aimed at identifying genomic alterations in tumors, and ... selective kinase inhibitors for a genetically defined patient ...
(Date:5/21/2013)... NANONEX CORPORATION, a pioneer and leading company ... successful delivery and installation of a new nanoimprint ... major Japanese manufacturing company. , ... lithography tool that has the ability to process ... types. Based on Nanonex inventions and proprietary technologies, ...
Breaking Biology Technology:The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 2The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 4The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 5Emerson Resources Announces CEO Retirement and Appointment of Successor 2Emerson Resources Announces CEO Retirement and Appointment of Successor 3Personal Genome Diagnostics And Blueprint Medicines Form Collaboration to Identify Novel Kinase Targets 2Personal Genome Diagnostics And Blueprint Medicines Form Collaboration to Identify Novel Kinase Targets 3Nanonex Announces the Shipment and Installation of an Innovative Nanoimprint Lithography System for Fully Automated Manufacturing 2
... BERLIN, July 13 The new ... appearance. An initiative recently,launched by Germany Trade & ... namely industrial biotechnology clusters and,chemical parks, in addition ... Germany,s biotechnology sector by creating new business,opportunities across ...
... Italy, July 13 Health Robotics today announced,that ... channel strategies,with direct investments in local infrastructure at ... distributors have been negatively affected by a,number of ... distributor,s,litigation with investors, and some financial difficulties supporting ...
... NATICK, Mass., July 13 Boston Scientific Corporation ... its LATITUDE(R) Patient Management system. The LATITUDE system remotely ... both the device and a patient,s heart health status. ... visits and send relevant data directly to a patient,s physician. ...
Cached Biology Technology:German Alliance for Industrial Biotechnology Debuts in Montreal 2Health Robotics Expands and Diversifies Global Channel Strategies With Joint-Ventures & Direct Operations 2Boston Scientific Announces European Approval for Its LATITUDE(R) Patient Management System 2Boston Scientific Announces European Approval for Its LATITUDE(R) Patient Management System 3Boston Scientific Announces European Approval for Its LATITUDE(R) Patient Management System 4
(Date:5/21/2013)... The concept of "place" is increasingly being considered ... now have a new resource that can help ... have with the places in their lives. ... a new book co-edited by the Pacific Northwest ... a human-centered approach to conservation. The book is ...
(Date:5/21/2013)... Cancers of all types become most deadly when ... cancer has reached this stage, it becomes very difficult ... that can develop. Now, researchers at the University of ... that target lymphoma tumor cells wherever they may be ... oncology in the MU College of Veterinary Medicine, says ...
(Date:5/21/2013)... The American Chemical Society (ACS), the world,s largest ... 246th National Meeting & Exposition, September 8-12, 2013, ... the Indiana Convention Center and at area hotels. ... discoveries that span science,s horizons from astronomy ... broadcast and online journalists a rich assortment of ...
Breaking Biology News(10 mins):MU researchers develop radioactive nanoparticles that target cancer cells 2
... for "horizontal" gene transfer, a new study has shown, similar ... become resistant to antibiotics and cause other serious problems. ... Nature , suggests that fungi have the capacity to rapidly ... plants and possibly animals, including humans. They are not ...
... patterned surfaces to influence the development of stem cells. ... many stem-cell biologists, who focus instead on uncovering the ... cells. "The cells are seeing the same soluble ... dictating whether they turn into fat or bone, and ...
... release is available in French . , ... extremely important process for the proper functioning and survival ... of ,cargo, to and from the surface of the ... consequences, leading to numerous diseases such as high cholesterol, ...
Cached Biology News:Fungi can change quickly, pass along infectious ability 2Getting turned on 2Getting turned on 3
BD BioCoat Laminin 150 mm Culture Dishes...
...
The BD CBA Human Apoptosis Kit can be used to quantitatively measure,cleaved PARP, Bcl-2, and active Caspase-3 protein levels in a single sample. The,Kit performance has been optimized for analysis o...
... package that provides crystallographers with an ... creation, set-up of experimental conditions and ... software helps crystallographers through the most ... Design of Crystallization ...
Biology Products: